Severe hepatitis B virus reactivation related to ibrutinib monotherapy-Reference-Cited by-同舟云学术

Severe hepatitis B virus reactivation related to ibrutinib monotherapy

Published:2017-01-05 Issue:4 Volume:96 Page:689-690
ISSN:0939-5555
Container-title:Annals of Hematology
language:en
Short-container-title:Ann Hematol

Author:

Herishanu Yair^ORCID,Katchman Helena,Polliack Aaron

Publisher

Springer Science and Business Media LLC

Subject

Hematology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00277-016-2917-2.pdf

Reference4 articles.

1. Wiestner A (2013) Targeting B-cell receptor signaling for anticancer therapy: the Bruton's tyrosine kinase inhibitor ibrutinib induces impressive responses in B-cell malignancies. J Clin Oncol 31:128–130

2. Sun C, Tian X, Lee YS et al (2015) Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib. Blood 126:2213–2219

3. Reddy KR, Beavers KL, Hammond SP et al (2015) American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:215–219 quiz e216-217

4. de Jesus Ngoma P, Kabamba B, Dahlqvist G et al (2015) Occult HBV reactivation induced by ibrutinib treatment: a case report. Acta Gastroenterol Belg 78:424–426

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of infections for patient treated with ibrutinib in clinical practice;Frontiers in Oncology;2024-09-10

2. Hepatitis B Virus Reactivation with Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia: A Case Report and Literature Review;Viral Hepatitis Journal;2024-04-01

3. Risk of Hepatitis B Reactivation in Patients Receiving Ibrutinib: The National Veterans Affairs Cohort;Open Forum Infectious Diseases;2024-01-10

4. HBV Reactivation in Patients Receiving Bruton Tyrosine Kinase Inhibitors (BTKIs): a Systematic Review and Meta-Analysis;Current Infectious Disease Reports;2024-01

5. Liver Pathology Related to Onco-Therapeutic Agents;Surgical Pathology Clinics;2023-09